Table 1.
Demographic and clinical data of the patients and median survival (Months ± SE), with percentages censored.
Table 2.
Comparison of the effects of different treatment protocols on median survival in lung cancer patients.
Table 3.
Comparison of the effects of triple therapy, platinum-based doublet chemotherapy with or without concurrent radiation, and single drug treatment on median survival in lung cancer patients.
Fig 1.
Survival analysis and number at risk of triple therapy in NSCLC patients.
Carboplatin/Gemcitabine+anti-PD-1/anti-PD-L1 mAb (Car/Ge+m), Carboplatin/Paclitaxel+anti-PD-1/anti-PD-L1 mAb (Car/Pa+m), Carboplatin/Pemetrexed+Erlotinib (Car/Pe+E), Cisplatin/Gemcitabine+anti-PD-1/anti-PD-L1 mAb (Cis/Ge+m), Cisplatin/Pemetrexed+Bevacizumab (Cis/Pe+B), Cisplatin/Pemetrexed+Erlotinib (Cis/Pe+E), Cisplatin/Pemetrexed+anti-PD-1/anti-PD-L1 mAb (Cis/Pe+m), Cisplatin/Vinorelbine+Bevacizumab (Cis/Vi+B), Cisplatin/Vinorelbine+anti-PD-1/anti-PD-L1 mAb (Cis/Vi+m).
Fig 2.
Survival analysis and number at risk of platinum-based doublet chemotherapy with or without concurrent radiation in NSCLC patients.
Carboplatin/Gemcitabine (Car/Ge), Carboplatin/Paclitaxel (Car/Pa), Carboplatin/Paclitaxel with concurrent Radiation (Car/Pa+R), Carboplatin/Pemetrexed (Car/Pe), Cisplatin/Docetaxel (Cis/Doc), Cisplatin/Gemcitabine (Cis/Ge), Cisplatin/Pemetrexed (Cis/Pe), Cisplatin/Vinorelbine (Cis/Vi), Cisplatin/Vinorelbine with concurrent Radiation (Cis/Vi+R).
Fig 3.
Survival analysis and number at risk of single therapy in NSCLC patients.
Epidermal growth factor inhibitors (EGFRI), anti-programmed death 1 (anti-PD-1)/anti-programmed death ligand 1 monoclonal antibodies (mAb).
Fig 4.
Survival analysis and number at risk of triple therapy, platinum-based doublet chemotherapy with or without concurrent radiation and single drug treatment in NSCLC patients.
Table 4.
Comparison of 1-year, 3-year, and 5-year survival rates between triple therapy, platinum-based doublet chemotherapy with or without concurrent radiation, and single-drug treatment.
Table 5.
Covariates proportional hazards assumption and hazard ratio.
Fig 5.
Covariates hazard ratio (95% CI) using Cox regression analysis.
Table 6.
Covariate effects on overall survival.
Table 7.
Metastasis of lung cancer to body organs and median survival of patients with different types of organ metastasis.
Fig 6.
The overall survival and number at risk of patients with different organ metastasis.
(M.O) multi organ metastasis, (No) no metastasis.